Brazilian Media: "Chinese Sinovac COVID-19 Vaccine Immune Effectiveness Below 60%"
Brazil Health Authorities "Details Missing"
Indonesian Health Authorities Announce 65%
[Asia Economy Reporter Hyunwoo Lee] Brazilian local media reported, citing Brazilian health authorities, that the immune efficacy of the Chinese pharmaceutical company Sinovac's COVID-19 vaccine was found to be below 60%. Previously, the immune efficacy of Sinovac's vaccine was reported differently by various authorities: 78% by the S?o Paulo state government in Brazil, 91% by Turkish health authorities, and 65% by Indonesian health authorities. Brazilian health authorities reportedly pointed out that detailed clinical information was missing from the vaccine data submitted by Sinovac.
According to UOL, a Brazilian news portal, on the 11th (local time), Brazilian health authorities confirmed that the immune efficacy of Sinovac's COVID-19 vaccine was between 50% and less than 60%, and it is planned to approve its emergency use on the 12th. Since the immune efficacy is above 50%, it is known that the vaccine passed the approval criteria of the Brazilian health authorities.
Sinovac's vaccine immune efficacy was previously announced as 65.3% by Indonesian health authorities, who approved its use the day before. Earlier, S?o Paulo state in Brazil announced 78%, and Turkish health authorities announced 91.25%, showing significant differences among the health authorities of each country.
Hot Picks Today
600 Million vs. 460 Million vs. 160 Million... Samsung Electronics DS Division: "Three Paychecks Under One Roof"
- Opening a Bank Account in Korea Is Too Difficult..."Over 150,000 Won in Notarization Fees Just for a Child's Account and Debit Card" [Foreigner K-Finance Status]②
- [Breaking] KOSPI, Buy Sidecar Activated
- "Disappointing Results: 80% of Sunscreens Found Lacking in Safety and Effectiveness"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
According to UOL, Sinovac applied for vaccine approval to Brazilian health authorities on the 8th. Regarding the reason why the immune efficacy was announced significantly lower than previously reported, a Brazilian health official stated, "Information such as the age, gender, and underlying diseases of participants in Sinovac's clinical trials was missing," and "Some details regarding the vaccine's immunogenicity and the number of participants during phase 3 clinical trials were also omitted," UOL reported.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.